PharmatecaPharmatecaФарматека2073-40342414-9128Bionika Media282388ArticlesСтатьиResearch ArticleEffektivnyy i bezopasnyy kontrol' glikemii s pomoshch'yu Diabetona MV: zalog uspeshnoy profilaktiki khronicheskikh oslozhneniy sakharnogo diabeta 2 tipaЭффективный и безопасный контроль гликемии с помощью Диабетона МВ: залог успешной профилактики хронических осложнений сахарного диабета 2 типаBiryukovaE. VБирюковаЕ. В

д.м.н, проф. кафедры эндокринологии и диабетологии

lena@obsudim.ruDanilovaT. BДаниловаТ. Б

Кафедра эндокринологии и диабетологии

МГМСУ им. А.И. Евдокимова200820132016NO16 (2013)№16 (2013)141925022023Copyright ©; 2013, Bionika MediaCopyright ©; 2013, ООО «Бионика Медиа»2013Bionika MediaООО «Бионика Медиа»https://journals.eco-vector.com/2073-4034/article/view/282388

Prevention of micro- and macrovascular complications of type 2 diabetes mellitus is an important goal of modern medicine. The article discusses the issues of treatment of the disease, the pharmacological characteristics, efficacy, and safety of sulfonylurea medications; the main benefits of gliclazide are described. The results of international studies that have demonstrated that the use of gliclazide contributes not only to the long-term metabolic control, but also to prevention or delay of development of vascular complications, are presented.

Предотвращение микро- и макрососудистых осложнений сахарного диабета 2 типа - важная задача современной медицины. Обсуждаются вопросы терапии заболевания, фармакологические характеристики, эффективность, безопасность препаратов сульфонилмочевины; отражены основные преимущества гликлазида. Приводятся результаты международных исследований, которые продемонстрировали, что применение гликлазида способствует не только обеспечению долгосрочного метаболического контроля, но и предотвращению или отсрочке развития сосудистых осложнений.

type 2 diabetes mellitushypoglycemiamacro- and microvascular complicationssulfonylurea medicationsgliclazideсахарный диабет 2 типагипогликемиимакро- и микрососудистые осложненияпрепараты сульфонилмочевиныгликлазидFonseca VA. Defining and Characterizing the Progression of Type 2 Diabetes. Diabetes Care 2009;32(suppl 2):151-56.Ruigomez A, Rodrigues LA. Presence of diabetes related complication at the time of NIDDM diagnosis: an important prognostic factor. Eur J Epidemiol 1998;14(15):439-45.Stumvoll M, Goldstein BJ, van Haeften TW. Pathogenesis of type 2 diabetes. Endocr Res 2007;32:19-37.Stratton IM, Adler AI, Neil HA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. Br Med J 2000;321:405-12.Giorgino F, Laviola L, Leonardini A. Pathoysiolody of type 2 diabetes: rationale for different oral antidiabetic treatment strategies. Diabetes Res Clin Pract 2005;68(1)22-9.Nyenwe EA, Jerkins TW, Umpierrez GE, Ki AE. Management of type 2 diabetes: evolving strategies for the treatment of patients with type 2 diabetes. Metab Clin and Experim 2011;60:1-23.Schmitz O, LundS, Andersen PH, etal. Optimizing insulin secretogogue therapy in patients with type 2 diabetes. Diabet Care 2002;25:342-46.Kimmel B, Inzucchi EM. Oral agents for type 2 diabetes: an Update. Clin Diabetes 2005;23(2):64-76.Tielmans A, Laloi-Michelin M, Coupaye M, et al. Drug treatment of type 2 diabetes. 2007;36(2):269-78.Gribble FM, Reimann F. Differential selectivity of insulin secretagogues: mechanisms, clinical implications, and drug interactions. J Diabetes Complications 2003;17:11-5.Aguilar-Bryan L, Nichols CG, Wechsler SF. Cloning of the в-cell high affinity sulfonylurea receptor: a regulator of insulin secretion. Science 1995;268:423-26.Khalangot M, Tronko M, Kravchenko V, Kovtun V. Glibenclamide-related excess in total and cardiovascular mortality risks: data from large Ukrainian observational cohort study. Diabetes Res Clin Pract. 2009;86(3):247-53.Van Staa T, Abenhaim L, Monette J. Rates of hypoglycemia in users of sulfonylureas. J Clin Epidemiol 1997;50:735-41.Stahl M, Berger W. Higher incidence of severe hypoglycemia leading to hospital admission in type 2 diabetic patients treated with long-acting versus short-acting sulfonylureas. Diabet Med. 1999;16:586-90.The ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008;358:2560-72.Gribble FM, Ashcroft FM. Differential sensitivity of beta-cell and extrapancreatic K(ATP) channels to gliclazide. Diabetologia 1999;42:845-48.Guillausseau PJ. Compliance and optimisation of oral antidiabetic therapy. A longitudinal study [in French]. Presse Med 2004;33:156-60.Shim WS, Kim SK, Kim HJ. Decremental of postprandial insulin secretion determines the progressive nature of type-2 diabetes. Eur J Endocrinol 2006;155(4):615-22.Cozma LS, Luzio SD, Dunseath GJ et al. Comparison of the effects of three insulinotropic drugs on plasma insulin levels after a standard meal. Diabetes Care 2002;25:1271-76.Guillausseau PJ, Greb W. 24-hour glycemic profile in type 2 diabetic patients treated with gliclazide modified release once daily. Diabetes Metab 2001;27:133-37.Hosker JP, Rudenski AS, Burnett MA et al. Similar reduction in first-and second-phase B-cell responsesat three different glucose levels in type II diabetes and the effect of gliclazide therapy. Metabolism 1989;38:767-72.Van Haeften TW, Veneman TF, Gerich JE, van der Veen EA. Influence of gliclazide on glucose-stimulated insulin release in man. Metabolism 1991;40:751-55.Khaled AA, Sekaran M, Ikram SI. Type 2 diabetes and vascular complications: A pathophysiologic view. Biomedical Research 2010;21(2): 147-55.Zoungas S, Patel A. Cardiovascular outcomes in type 2 diabetes: the impact of preventative therapies. Ann N YAcad Sci 2010;1212(1):29-40.Bloomgarden ZT. Cardiovascular disease in diabetes. Diabetes Care 2008;31(6):1260-66.Дедов И.И., Александров А.А. Диабетическое сердце: Causa Magna. Сердце 2004; 3:1: 5-8.Robertson RP, Harmon J, Tran POT, Poitout V. в-Cell glucose toxicity, lipotoxicity, and chronic oxidative stress in type 2 diabetes. Diabetes. 2004;53(suppl1):119-24.Jennings P, Scott NA, Saniabadi AR, Belch JFF. Effects of gliclazide on platelet reactivity and free radicals in type II diabetic patients: clinical assessement. Metabolism. 1992; 5:36-9.Sliwinska A, Rogalska A, Szwed M, et al. Gliclazide may have an antiapoptotic effect related to its antioxidant properties in human normal and cancer cells. Mol Biol Rep 2012;39(5):5253-67.Jennings PE. Vascular benefits of gliclazide beyond glycemic control. Metabolism 2000;49:17-20.Maddock HL, Siedlecka SM, Yellon DM. Myocardial protection from either ischaemic preconditioning or nicorandil is not blocked by gliclazide. Cardiovasc. Drugs Ther 2004;18:113-19.Schramm TK, Gislason GH, Vaag A, et al. Mortality and cardiovascular risk associated with different insulin secretagogues compared with metformin in type 2 diabetes, with or without a previous myocardial infarction: a nationwide study. Eur Heart J 2011; 32(15):1900-908.Abdelmoneim AS, Eurich DT, Gamble JM et al. Risk of acute coronary events associated with glyburide compared to gliclazide use in patients with type 2 diabetes: A nested case-control Ssudy. Diabetes Obes Metab 2013:10.1111/ dom.12173.Moen MF, Zhan M, Hsu VH. Frequency of hypoglycemia and its significance in chronic kidney disease. Clin J Am Soc Nephrol 2009;4(6):1121-27.Van Staa T, Abenhaim L, Monette J. Rates of hypoglycemia in users of sulfonylureas. J Clin Epidemiol. 1997;50:735-41.Stahl M, Berger W. Higher incidence of severe hypoglycemia leading to hospital admission in type 2 diabetic patients treated with long-acting versus short-acting sulfonylureas. Diabet Med 1999;16:586-90.Sifri SA, Basiounny A, Echtay A, et al. The incidence of hypoglycaemia in Muslim patients with type 2 diabetes treated with sitagliptin or a sulphonylurea during Ramadan: a randomised trial Int J Clin Pract 2011;65(11):1132-40.Aravind SR, Ismail SB, Balamurugan R. Hypoglycemia in patients with type 2 diabetes from India and Malaysia treated with sitagliptin or a sulfonylurea during Ramadan: a randomized, pragmatic study. Current Medical Research & Opinion 2012;28(8):1-8.Шестакова М.В., Викулова О.К. Результаты открытой наблюдательной программы DIAMOND // Сахарный диабет 2011. № 3 С. 90-6.